Incyte Reports 2018 Second Quarter Financial Results and Updates on Key Clinical Programs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Incyte (INCY) PT Lowered to $72 at RBC Capital
August 1, 2018 8:50 AM EDTRBC Capital lowered its price target on Incyte (NASDAQ: INCY) to $72.00 (from $74.00) while maintaining a Sector Perform rating.
... MoreIncyte (INCY) Q2 Revenue Tops Views
July 31, 2018 7:13 AM EDTIncyte (NASDAQ: INCY) reported Q2 EPS of $0.26, $0.09 worse than the analyst estimate of $0.35. Revenue for the quarter came in at $521.52 million versus the consensus estimate of $473.78 million.
2018 Financial... More
